Among potential targeting agents for prostate cancer, prostate specific membrane antigen (PSMA) ligands have been employed with great success in preclinical and clinical studies for PET imaging and radionuclide therapies; this is because prostate cancers consistently overexpress PSMA [17,18]. The gene discussed is FOLH1; the disease is prostate carcinoma.